

Introduction

Lewis Y (Le^y) is a tumour-associated, tetrasaccharide antigen expressed on the surface of various tumour cells. The antigen is a target of therapeutic monoclonal antibodies (BR96) and is proposed as a glycoconjugate cancer vaccine.¹ Active research on synthetic cancer vaccines has yet to establish the optimal structure for the presentation of synthetic carbohydrate antigens to the immune system.

As a step towards resolving the effect of antigen size on vaccine immunogenicity, two extended Le^y epitopes have been synthesized and will be conjugated to BSA (1 and 2) .²⁻⁴ By incorporating portions of lactose and a truncated ceramide, the extended antigen approximates the Le^y epitope as it occurs in glycolipids (Fig. 1) on the surface of tumor cells (Fig. 2).

- 1. Kudryashov, V., Glunz, P. W., Williams, L. J., Hintermann, S., Danishefsky, S. J., Lloyd, K. O. Proc. Natl. Acad. Sci. USA 98, 3264-3269 (2001)
- 2. Fernandez-Santana, V., Gonazalez-Lio, R., Sarracent-Perez, J., Verez-Bencomo, V. *Glycoconjugate J.* **15**, 549-553 (1998)
- 3. Jue, R., Lambert, J. M., Pierce, L. R., Traut, R. R. *Biochemistry* **17**, 5399-5406 (1978)
- 4. Rose, B. G, Kamps-Holtzapple, C., Stanker, L. H. *Bioconjugate Chem*. 6, 529-535 (1995)



Synthetic Studies Toward Lewis Y Glycoconjugates Lesley Liu, Chang-Chun Ling and David R. Bundle

Department of Chemistry, University of Alberta, Edmonton, AB, Canada, T6G 2G2



Acknowledgements

We thank Dr. P. Zhang and C. Nycholat for supplying the truncated azidosphingosine acceptor. This work was supported by a NSERC Research Grant and a postgraduate studentship.

